Voretigen Neparvovec (2, reassessment) (Luxturna®) – Hereditary retinal dystrophy

Characteristics

Start date 01.04.2022
Resolution 15.09.2022
INN Voretigen Neparvovec
Brand name Luxturna®
Pharm. company Novartis Pharma GmbH
G-BA procedure ID 2022-04-01-D-803
Therapeutic area Eye diseases ORPHAN
Reason for procedure Reassessment: G-BA limitation
Original resolution: Voretigen Neparvovec (17.10.2019)

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Luxturna is used to treat adult and paediatric patients with Vision loss due to hereditary retinal dystrophy resulting from proven biallelic RPE65 mutations and who have sufficient viable retinal cells.

Subpopulation Indication Comparator
Adult and paediatric patients with visual loss due to hereditary retinal dystrophy based on proven biallelic RPE65 mutations and who have sufficient viable retinal cells. Not applicable

9. Associated procedures



<< List of all resolutions